MX2016015261A - Dispersion solida de allisartan isoproxilo y su composicion. - Google Patents

Dispersion solida de allisartan isoproxilo y su composicion.

Info

Publication number
MX2016015261A
MX2016015261A MX2016015261A MX2016015261A MX2016015261A MX 2016015261 A MX2016015261 A MX 2016015261A MX 2016015261 A MX2016015261 A MX 2016015261A MX 2016015261 A MX2016015261 A MX 2016015261A MX 2016015261 A MX2016015261 A MX 2016015261A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
solid dispersion
allisartan isoproxil
isoproxil solid
good
Prior art date
Application number
MX2016015261A
Other languages
English (en)
Inventor
Ye Guanhao
BU Shui
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of MX2016015261A publication Critical patent/MX2016015261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una dispersión sólida de allisartan isoproxilo con alta carga y estabilidad del fármaco. También se divulga una composición farmacéutica de allisartan isoproxilo que comprende la dispersión sólida. La composición farmacéutica que allisartan isoproxilo tiene las ventajas de alta estabilidad, buena solubilidad, buena tolerancia del paciente, etc.
MX2016015261A 2014-05-23 2015-05-20 Dispersion solida de allisartan isoproxilo y su composicion. MX2016015261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410223097 2014-05-23
PCT/CN2015/079352 WO2015176655A1 (zh) 2014-05-23 2015-05-20 一种阿利沙坦酯固体分散体及药物组合物

Publications (1)

Publication Number Publication Date
MX2016015261A true MX2016015261A (es) 2017-08-15

Family

ID=54553430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015261A MX2016015261A (es) 2014-05-23 2015-05-20 Dispersion solida de allisartan isoproxilo y su composicion.

Country Status (11)

Country Link
US (1) US20170135989A1 (es)
EP (1) EP3146962A4 (es)
JP (1) JP2017518985A (es)
KR (1) KR20170009897A (es)
CN (1) CN105078974A (es)
AU (1) AU2015263635A1 (es)
CA (1) CA2949154A1 (es)
MX (1) MX2016015261A (es)
RU (1) RU2016150178A (es)
TW (1) TW201545745A (es)
WO (1) WO2015176655A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105232489B (zh) * 2014-07-01 2019-06-11 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物
CN107441497A (zh) * 2016-05-31 2017-12-08 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及其制备方法及含有该固体分散体的制剂
CN107648185A (zh) * 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
CN108125918B (zh) * 2018-01-12 2020-06-23 杭州中美华东制药有限公司 依维莫司药物组合物
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114306263B (zh) * 2021-01-20 2023-07-04 深圳信立泰药业股份有限公司 一种复方降压药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) * 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101066264A (zh) * 2007-06-12 2007-11-07 杨喜鸿 奥美沙坦酯的固体分散体及其制备方法和药物应用
CN101367795B (zh) * 2007-08-17 2012-05-02 上海艾力斯生物医药有限公司 一种咪唑-5-羧酸衍生物及其制备方法
CA2769177A1 (en) * 2009-07-28 2011-02-03 Takeda Pharmaceutical Company Limited Tablet
CN102178642A (zh) * 2011-04-29 2011-09-14 苏州大学 一种替米沙坦固体分散体及其制备方法
WO2012159511A1 (zh) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 阿齐沙坦固体分散体及其制备方法和药物组合物
CN102793680A (zh) * 2011-05-23 2012-11-28 江苏恒瑞医药股份有限公司 阿齐沙坦固体分散体及其制备方法和药物组合物
CN102357078A (zh) * 2011-10-17 2012-02-22 苏州大学 一种缬沙坦固体分散体及其制备方法
KR101375290B1 (ko) * 2012-02-10 2014-03-20 한국콜마주식회사 발사르탄을 함유하는 고형 경구제형의 제조방법
KR101441450B1 (ko) * 2012-10-22 2014-09-24 충남대학교산학협력단 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도

Also Published As

Publication number Publication date
JP2017518985A (ja) 2017-07-13
US20170135989A1 (en) 2017-05-18
RU2016150178A3 (es) 2018-06-26
EP3146962A4 (en) 2017-11-29
TW201545745A (zh) 2015-12-16
CA2949154A1 (en) 2015-11-26
RU2016150178A (ru) 2018-06-26
EP3146962A1 (en) 2017-03-29
WO2015176655A1 (zh) 2015-11-26
CN105078974A (zh) 2015-11-25
AU2015263635A1 (en) 2016-11-24
KR20170009897A (ko) 2017-01-25

Similar Documents

Publication Publication Date Title
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CA2956871C (en) Compounds active towards bromodomains
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2016005395A (es) Formulacion estable de insulina glulisina.
CL2015002897A1 (es) Inhibidores de bace1
PH12016501841A1 (en) Immunosuppressant formulation
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2020004205A (es) Composiciones antibioticas de ceftolozano.
EP3275482A4 (en) Syringe holder and medical solution administration set
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EP3534961A4 (en) STABLE AQUEOUS INJECTABLE CAPSAICIN FORMULATIONS AND MEDICAL USES THEREOF
EP3153195A4 (en) Syringe cap, needle-mounted syringe, and prefilled syringe formulation
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
IN2013MU01985A (es)
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
EP3297636A4 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.